PL2291080T3 - Nowe modulatory receptorów sfingozyno-1-fosforanu - Google Patents
Nowe modulatory receptorów sfingozyno-1-fosforanuInfo
- Publication number
- PL2291080T3 PL2291080T3 PL09762826T PL09762826T PL2291080T3 PL 2291080 T3 PL2291080 T3 PL 2291080T3 PL 09762826 T PL09762826 T PL 09762826T PL 09762826 T PL09762826 T PL 09762826T PL 2291080 T3 PL2291080 T3 PL 2291080T3
- Authority
- PL
- Poland
- Prior art keywords
- phosphate receptors
- novel modulators
- sphingosine phosphate
- sphingosine
- modulators
- Prior art date
Links
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12760308P | 2008-05-14 | 2008-05-14 | |
| EP09762826.7A EP2291080B1 (en) | 2008-05-14 | 2009-05-14 | Novel modulators of sphingosine phosphate receptors |
| PCT/US2009/003014 WO2009151529A1 (en) | 2008-05-14 | 2009-05-14 | Novel modulators of sphingosine phosphate receptors |
| US12/465,767 US8796318B2 (en) | 2008-05-14 | 2009-05-14 | Modulators of sphingosine phosphate receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2291080T3 true PL2291080T3 (pl) | 2015-12-31 |
Family
ID=41416994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15158887T PL2913326T3 (pl) | 2008-05-14 | 2009-05-14 | Nowe modulatory receptorów fosforanu sfingozyny |
| PL09762826T PL2291080T3 (pl) | 2008-05-14 | 2009-05-14 | Nowe modulatory receptorów sfingozyno-1-fosforanu |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15158887T PL2913326T3 (pl) | 2008-05-14 | 2009-05-14 | Nowe modulatory receptorów fosforanu sfingozyny |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US8796318B2 (pl) |
| EP (3) | EP2291080B1 (pl) |
| JP (2) | JP5837417B2 (pl) |
| AU (2) | AU2009258242B2 (pl) |
| CY (2) | CY1123338T1 (pl) |
| DK (1) | DK2291080T3 (pl) |
| EA (1) | EA021672B1 (pl) |
| ES (2) | ES2549761T3 (pl) |
| FI (2) | FI2291080T5 (pl) |
| HR (1) | HRP20150982T1 (pl) |
| HU (2) | HUE025984T2 (pl) |
| LT (1) | LTC2291080I2 (pl) |
| MY (2) | MY172105A (pl) |
| NL (1) | NL301065I2 (pl) |
| NO (1) | NO2020034I1 (pl) |
| NZ (1) | NZ589617A (pl) |
| PL (2) | PL2913326T3 (pl) |
| PT (2) | PT2913326T (pl) |
| SI (1) | SI2291080T1 (pl) |
| WO (1) | WO2009151529A1 (pl) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007292993B2 (en) | 2006-09-07 | 2013-01-24 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
| NZ580454A (en) | 2007-03-16 | 2011-05-27 | Actelion Pharmaceuticals Ltd | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
| PT2195311E (pt) | 2007-08-17 | 2011-05-25 | Actelion Pharmaceuticals Ltd | Derivados de piridina como moduladores do receptor s1p1/edg1 |
| CA2700917A1 (en) | 2007-11-01 | 2009-05-07 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
| KR20100095593A (ko) | 2007-12-10 | 2010-08-31 | 액테리온 파마슈티칼 리미티드 | Ｓ１ｐ１/ｅｄｇ１의 작동약으로서 티오펜 유도체 |
| JP5481395B2 (ja) | 2008-03-07 | 2014-04-23 | アクテリオン ファーマシューティカルズ リミテッド | 新規なアミノメチルベンゼン誘導体 |
| AU2009258242B2 (en) | 2008-05-14 | 2015-07-16 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| HUE043090T2 (hu) | 2008-06-09 | 2019-08-28 | Univ Muenchen Ludwig Maximilians | Gyógyszerek fehérjék aggregálódásának gátlására olyan betegségeknél, amelyek fehérje-aggregálódással és/vagy neurodegeneratív megbetegedésekkel függnek össze |
| US20100010053A1 (en) * | 2008-06-20 | 2010-01-14 | Jose Luis Castro Pineiro | Compounds |
| KR20190004843A (ko) | 2008-07-23 | 2019-01-14 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| JP5726737B2 (ja) | 2008-08-27 | 2015-06-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
| WO2010085582A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| WO2010085584A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| SI2454255T1 (sl) | 2009-07-16 | 2014-01-31 | Actelion Pharmaceuticals Ltd. | Derivati piridin-4-ila kot agonisti s1p1/edg1 |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| RS61829B1 (sr) * | 2009-11-13 | 2021-06-30 | Receptos Llc | Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze |
| RS57070B1 (sr) * | 2009-11-13 | 2018-06-29 | Celgene Int Ii Sarl | Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza |
| AU2015202660B2 (en) * | 2009-11-13 | 2016-10-27 | Receptos Llc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| AU2010319982B2 (en) * | 2009-11-13 | 2016-02-04 | Receptos Llc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| CN108558740B (zh) | 2010-01-27 | 2021-10-19 | 艾尼纳制药公司 | S1p1受体调节剂及其盐的制备方法 |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| EP2390252A1 (en) * | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| WO2012040532A1 (en) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| KR101869120B1 (ko) | 2011-01-19 | 2018-06-19 | 이도르시아 파마슈티컬스 리미티드 | 2-메톡시-피리딘-4-일 유도체 |
| US8865754B2 (en) | 2011-03-03 | 2014-10-21 | Proteotech Inc. | Compounds for the treatment of neurodegenerative diseases |
| CN102718726A (zh) * | 2011-03-31 | 2012-10-10 | 上海铂力生物科技有限公司 | 作为免疫调节剂的(z)-5-苯亚甲基噻唑啉-4-酮衍生物 |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| CA2894281C (en) | 2012-12-20 | 2021-04-20 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| PT2958913T (pt) | 2013-02-20 | 2018-12-03 | Lg Chemical Ltd | Agonistas de recetores de esfingosina-1-fosfato, métodos para a sua preparação e composições farmacêuticas que os contêm como agente ativo |
| MX363545B (es) * | 2013-03-15 | 2019-03-27 | Idorsia Pharmaceuticals Ltd | Derivados piridin-4-ilo. |
| EP3041826A4 (en) | 2013-09-06 | 2017-02-15 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| EP2853532B1 (en) * | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
| WO2015066515A1 (en) * | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| AU2015281799B2 (en) * | 2014-06-26 | 2019-11-28 | Central Adelaide Local Health Network Incorporated | Enzyme interacting agents |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| AU2016246398A1 (en) | 2015-04-06 | 2017-10-26 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
| ES2770348T3 (es) | 2015-05-20 | 2020-07-01 | Idorsia Pharmaceuticals Ltd | Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol |
| HUE060476T2 (hu) | 2015-06-22 | 2023-03-28 | Arena Pharm Inc | (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra |
| ES3022204T3 (en) | 2016-06-14 | 2025-05-28 | Receptos Llc | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
| WO2018033149A1 (zh) | 2016-08-19 | 2018-02-22 | 苏州科睿思制药有限公司 | 奥扎莫德的晶型及其制备方法 |
| CN109640982A (zh) | 2016-09-14 | 2019-04-16 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| EP3518922B1 (en) | 2016-09-29 | 2026-02-11 | Receptos LLC | Compounds and methods for treating lupus |
| WO2018136893A1 (en) | 2017-01-23 | 2018-07-26 | Naqi Logics, Llc | Apparatus, methods, and systems for using imagined direction to define actions, functions, or execution |
| CN110545848A (zh) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
| WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| US10981900B2 (en) * | 2017-02-28 | 2021-04-20 | Medshine Discovery Inc. | Spiro compound and use thereof |
| WO2018211323A1 (en) * | 2017-05-17 | 2018-11-22 | Oppilan Pharma Ltd. | Hetercyclic compounds for the treatment of disease |
| US11117876B2 (en) | 2017-08-31 | 2021-09-14 | Receptos Llc | Crystalline form of ozanimod hydrochloride, and processes for preparation thereof |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| US12156866B2 (en) | 2018-06-06 | 2024-12-03 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| EP3847158A1 (en) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
| WO2020152718A1 (en) | 2019-01-25 | 2020-07-30 | Mylan Laboratories Limited | Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile |
| CN114008034A (zh) * | 2019-04-26 | 2022-02-01 | 瑞塞普托斯公司 | 1-磷酸鞘氨醇受体调节剂 |
| CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
| WO2021026479A1 (en) * | 2019-08-07 | 2021-02-11 | Stamford, Andrew | Small molecule inhibitors of s1p2 receptor and uses thereof |
| EP4076448A4 (en) | 2019-12-20 | 2024-03-27 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| KR20220158743A (ko) * | 2020-03-27 | 2022-12-01 | 리셉토스 엘엘씨 | 스핑고신 1 포스페이트 수용체 조절제 |
| EP4126828A1 (en) * | 2020-03-27 | 2023-02-08 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| WO2021195396A1 (en) * | 2020-03-27 | 2021-09-30 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| WO2021207051A1 (en) * | 2020-04-06 | 2021-10-14 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
| US20230233532A1 (en) * | 2020-06-26 | 2023-07-27 | The Penn State Research Foundation | Sphingosine-1-phosphate receptor 1 agonist and liposomal formulations thereof |
| CA3191164A1 (en) * | 2020-08-10 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28 |
| EP4333841A1 (en) | 2021-05-04 | 2024-03-13 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
| WO2024117172A1 (ja) | 2022-11-30 | 2024-06-06 | 花王株式会社 | 痒みの予防又は改善剤 |
| WO2024246174A1 (en) | 2023-05-31 | 2024-12-05 | Química Sintética, S.A. | Amorphous and crystalline form of ozanimod hydrochloride |
| CN119320366B (zh) * | 2023-07-17 | 2025-11-18 | 中国医学科学院药物研究所 | 取代萘甲基噁二唑-苯胺类化合物及其用途 |
| US11905265B1 (en) * | 2023-10-13 | 2024-02-20 | King Faisal University | 3,4-dimethoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL31990A (en) * | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
| ATE249455T1 (de) | 1998-01-23 | 2003-09-15 | Sankyo Co | Spiropiperidin-derivate |
| DE10240818A1 (de) | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| CA2509218C (en) | 2002-12-20 | 2010-09-07 | Merck & Co., Inc. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists |
| CN100441185C (zh) | 2003-04-30 | 2008-12-10 | 麦克弗罗斯特加拿大有限公司 | 8-(3-联芳基)苯基喹啉磷酸二酯酶-4抑制剂 |
| WO2004110351A2 (en) * | 2003-05-14 | 2004-12-23 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis c virus |
| AU2004277947A1 (en) | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
| CN1894225A (zh) | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| WO2005058845A2 (en) * | 2003-12-19 | 2005-06-30 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| DK1650186T3 (da) | 2004-10-22 | 2008-10-13 | Sun Pharmaceutical Ind Ltd | Nye dicarboxylsyrederivater |
| JP2008531546A (ja) | 2005-02-22 | 2008-08-14 | テバ ファーマシューティカル インダストリーズ リミティド | エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス |
| EP1893591A1 (en) | 2005-06-08 | 2008-03-05 | Novartis AG | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| MX2007015675A (es) | 2005-07-04 | 2008-02-20 | Novo Nordisk As | Antagonistas del receptor de histamina h3. |
| CN101346372B (zh) | 2005-12-23 | 2011-09-28 | 弗·哈夫曼-拉罗切有限公司 | 芳基-异*唑-4-基-*二唑衍生物 |
| TWI382984B (zh) * | 2006-04-03 | 2013-01-21 | Astellas Pharma Inc | 雜環化合物 |
| US20080015193A1 (en) * | 2006-06-20 | 2008-01-17 | Mendoza Jose S | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof |
| US20080009534A1 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| MX2009003129A (es) | 2006-09-29 | 2009-04-06 | Novartis Ag | Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras. |
| JP2010510250A (ja) * | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ |
| CN101562977A (zh) | 2006-12-15 | 2009-10-21 | 艾博特公司 | 新的二唑化合物 |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| US20090188269A1 (en) | 2008-01-25 | 2009-07-30 | Henkel Corporation | High pressure connection systems and methods for their manufacture |
| DK2913326T3 (da) | 2008-05-14 | 2020-08-17 | Scripps Research Inst | Hidtil ukendte modulatorer af sphingosinphosphatreceptorer |
| AU2009258242B2 (en) | 2008-05-14 | 2015-07-16 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
-
2009
- 2009-05-14 AU AU2009258242A patent/AU2009258242B2/en active Active
- 2009-05-14 WO PCT/US2009/003014 patent/WO2009151529A1/en not_active Ceased
- 2009-05-14 PT PT151588878T patent/PT2913326T/pt unknown
- 2009-05-14 EA EA201001785A patent/EA021672B1/ru unknown
- 2009-05-14 SI SI200931271T patent/SI2291080T1/sl unknown
- 2009-05-14 JP JP2011509488A patent/JP5837417B2/ja active Active
- 2009-05-14 PL PL15158887T patent/PL2913326T3/pl unknown
- 2009-05-14 PL PL09762826T patent/PL2291080T3/pl unknown
- 2009-05-14 MY MYPI2015000801A patent/MY172105A/en unknown
- 2009-05-14 HU HUE09762826A patent/HUE025984T2/hu unknown
- 2009-05-14 ES ES09762826.7T patent/ES2549761T3/es active Active
- 2009-05-14 EP EP09762826.7A patent/EP2291080B1/en active Active
- 2009-05-14 DK DK09762826.7T patent/DK2291080T3/en active
- 2009-05-14 ES ES15158887T patent/ES2813368T3/es active Active
- 2009-05-14 MY MYPI2010005338A patent/MY156381A/en unknown
- 2009-05-14 US US12/465,767 patent/US8796318B2/en active Active
- 2009-05-14 FI FIEP09762826.7T patent/FI2291080T5/fi active
- 2009-05-14 EP EP15158887.8A patent/EP2913326B1/en active Active
- 2009-05-14 PT PT97628267T patent/PT2291080E/pt unknown
- 2009-05-14 NZ NZ589617A patent/NZ589617A/en unknown
- 2009-05-14 EP EP20185750.5A patent/EP3782991A1/en not_active Withdrawn
- 2009-05-14 HR HRP20150982TT patent/HRP20150982T1/hr unknown
-
2012
- 2012-09-06 US US13/605,358 patent/US8530503B2/en active Active
- 2012-09-06 US US13/605,427 patent/US8466183B2/en active Active
- 2012-09-06 US US13/605,561 patent/US8481573B2/en active Active
-
2014
- 2014-06-23 US US14/311,825 patent/US9382217B2/en active Active
-
2015
- 2015-08-12 AU AU2015213309A patent/AU2015213309B2/en active Active
- 2015-11-05 JP JP2015217236A patent/JP2016041736A/ja active Pending
-
2016
- 2016-06-21 US US15/188,132 patent/US20170050941A1/en not_active Abandoned
-
2017
- 2017-09-22 US US15/713,237 patent/US9975863B2/en active Active
-
2018
- 2018-04-23 US US15/959,935 patent/US10544136B2/en active Active
-
2020
- 2020-09-11 CY CY20201100862T patent/CY1123338T1/el unknown
- 2020-09-24 FI FIC20200037C patent/FIC20200037I1/fi unknown
- 2020-09-29 NO NO2020034C patent/NO2020034I1/no unknown
- 2020-09-30 NL NL301065C patent/NL301065I2/nl unknown
- 2020-10-01 LT LTPA2020529C patent/LTC2291080I2/lt unknown
- 2020-10-01 HU HUS2000038C patent/HUS2000038I1/hu unknown
- 2020-10-02 CY CY2020033C patent/CY2020033I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2000038I1 (hu) | Szfingozin foszfát receptor új modulátorai | |
| IL209306A0 (en) | Novel modulators of sphingosine phosphate receptors | |
| IL236272A0 (en) | TLRS modulators | |
| EP2344446A4 (en) | S1P RECEPTOR MODULATORS | |
| PL2477987T3 (pl) | Modulatory receptorów toll-podobnych | |
| PL2465492T3 (pl) | Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P) | |
| IL219692A0 (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
| PL2354134T3 (pl) | Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny | |
| IL219690A0 (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| IL210067A0 (en) | Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors | |
| ZA201006932B (en) | Modulators of dopamine neurotransmission | |
| EP2166848A4 (en) | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | |
| IL205044A0 (en) | Amide linked modulators of ?? - secretase | |
| IL205041A0 (en) | Amine linked modulators of ?? - secretase | |
| AP2859A (en) | Modulators of toll-like receptors | |
| EP2297579A4 (en) | DETERMINING A DISTRIBUTION | |
| HK1175653A (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| HK1196526A (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
| ZA201200879B (en) | Novel compounds as modulators of glucocorticoid receptors |